

INVITATION

FRIDAY
04
NOVEMBER
2022

7th NORDIC PHOTOPHERESIS MEETING

Clarion Hotel Oslo, Dronning
Eufemias gate 15, 0191 Oslo, Norway

This information is intended for healthcare professionals in Europe

Leader Chair **Prof Gösta Berlin**, Linköping University Hospital, Sweden

09:00 – 09:30 **Registration & coffee**

SESSION 1

09:30 – 10:00 **The challenge of managing cGvHD**

Prof Andrea Bacigalupo, Fondazione Policlinico Gemelli, Rome, Italy

10:00 – 10:25 **Current preventative strategies in GvHD**

Prof Tobias Gedde-Dahl, Oslo University Hospital, Norway

10:25 – 10:50 **Special patient cases – How would you manage this?**

Prof Andrea Bacigalupo, Fondazione Policlinico Gemelli, Rome, Italy

10:50 – 11:00 **Q&A Session 1**

11:00 – 11:15 **Break**

SESSION 2

11:15 – 11:45 **Real-world treatment patterns and outcomes in cGvHD patients treated with ECP**

Prof Gösta Berlin, Linköping University Hospital, Sweden

11:45 – 12:10 **How to manage acute GvHD with the right treatment for the right patient**

Prof Robert Zeiser, University Hospital Freiburg, Germany

12:10 – 12:35 **How to manage chronic GvHD with the right treatment for the right patient**

Prof Robert Zeiser, University Hospital Freiburg, Germany

12:35 – 13:00 **Q&A Session 2**

13:00 – 14:00 **Lunch**

SESSION 3

14:00 – 14:40 **The importance of QoL in GvHD patients**

Prof Daniel Wolff, University Hospital Regensburg, Germany

14:40 – 14:55 **Latest news on Nordic ECP Quality group**

Prof Gösta Berlin, Linköping University Hospital, Sweden

14:55 – 15:15 **Q&A Session 3**

To register your interest please email josephine.stapnes@mnk.com

ECP: Extracorporeal Photopheresis, GvHD: Graft versus Host Disease, cGvHD: Chronic Graft versus Host Disease, QoL: Quality of Life

All speakers are subject to contract.

**This is a commercial programme run by Therakos (UK) Ltd,
a Mallinckrodt Company.**

Follow the
Therakos Institute



[Privacy policy](#)

For more information on THERAKOS ECP Immunomodulation™ please visit www.therakos.eu
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt
company. Other brands are trademarks of a Mallinckrodt company or their respective owners.
© 2022 Mallinckrodt. Item code: EU-2200253. Date of preparation: September 2022.

*Although we have determined that we have a legitimate interest in using your data for marketing
and sales purposes as per the terms of the current data protection legislation, you can opt-out
by replying to this mail indicating “unsubscribe” in the email body. Our privacy policy provides
additional information.*